Skip to main content
    V

    Viking Therapeutics Inc (VKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.80
    -2.42 (-8.28%)

    Market Cap: $3.73B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Viking Therapeutics Inc (VKTX) Financials: Revenue, Profit and Cash Flow

    Updated Oct 28, 2026. Financial statements from company filings, amounts in US dollars.

    Viking Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$359.64M, operating cash flow was -$278.69M and free cash flow was -$278.69M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$183.19M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $393.34M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$344.95M$101.64M$63.81M$54.23M$44.98M$31.93M$23.56M$19.04M$13.74M$9.00M
    Operating income-$393.34M-$150.92M-$100.83M-$70.36M-$55.68M-$42.66M-$32.69M-$26.16M-$19.07M-$13.85M
    Net income-$359.64M-$109.96M-$85.89M-$68.87M-$54.99M-$39.49M-$25.78M-$22.06M-$20.58M-$14.73M
    EBITDAN/AN/AN/A-$68.83M-$51.45M-$35.37M-$31.81M-$23.63M-$16.35M-$10.84M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$0$0$436.00K
    Gross profit$0$0$0-$94.00K$0$0$0-$110.00K$0$0$0-$74.00K
    Operating income-$187.11M-$132.60M-$164.13M-$164.74M-$98.56M-$74.57M-$55.47M-$46.24M-$36.56M-$34.05M-$34.07M-$29.29M
    Net income-$183.19M-$128.02M-$158.32M-$157.66M-$90.79M-$65.56M-$45.63M-$35.42M-$24.94M-$22.25M-$27.36M-$24.61M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $137.00K by $165.67M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$715.73M$908.32M$368.49M$168.53M$210.66M$256.50M$284.26M$302.31M$22.12M$14.54M
    Current assets$715.60M$907.22M$367.23M$167.04M$210.53M$256.10M$283.50M$302.13M$21.85M$13.97M
    Cash and equivalents$165.81M$26.68M$55.52M$36.63M$26.37M$29.12M$8.38M$24.78M$8.99M$3.08M
    Total liabilities$76.67M$28.04M$20.07M$23.21M$8.78M$12.16M$7.14M$4.56M$8.66M$6.49M
    Short-term debt$137.00K$489.00K$324.00K$304.00K$29.00K$330.00K$302.00KN/A$3.45M$3.27M
    Shareholder equity$639.06M$880.28M$348.42M$145.32M$201.88M$244.34M$277.12M$297.75M$13.46M$8.04M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$977.17M$521.90M$608.24M$715.73M$739.41M$827.85M$866.99M$908.32M$937.89M$946.84M$967.52M$368.49M
    Total liabilities$388.57M$113.58M$106.33M$76.67M$26.39M$32.39M$20.07M$28.04M$26.44M$25.86M$33.63M$20.07M
    Cash and equivalents$677.61M$125.75M$118.12M$165.81M$100.38M$33.88M$37.94M$26.68M$50.35M$43.91M$195.58M$55.52M
    Shareholder equity$588.60M$408.32M$501.92M$639.06M$713.03M$795.46M$846.92M$880.28M$911.45M$920.98M$933.89M$348.42M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$278.69M-$87.79M-$73.38M-$48.40M-$47.59M-$21.78M-$24.75M-$18.75M-$14.76M-$11.07M
    Free cash flow-$278.69M-$87.79M-$73.38M-$48.40M-$47.59M-$21.78M-$24.75M-$18.75M-$14.76M-$11.07M
    Dividends paidN/AN/AN/AN/AN/AN/AN/AN/A$0$22.29K
    Share repurchases$0$0$0$6.79M$0$26.00K$73.00KN/A$500.00K$1.10M
    Investing cash flow$341.39M-$553.37M-$179.09M$54.75M$37.96M$41.57M$7.46M-$265.73M-$1.73M$3.03M
    Financing cash flow$76.44M$612.46M$271.38M$4.16M$6.88M$950.00K$887.00K$300.27M$22.40M$10.35M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$138.19M-$125.17M-$113.98M-$85.29M-$94.00M-$47.06M-$52.33M-$31.18M-$21.96M-$28.51M-$6.13M-$17.64M
    Free cash flowN/AN/A-$113.98M-$85.29M-$94.00M-$47.06M-$52.33M-$31.18M-$21.96M-$28.51M-$6.13M-$17.64M
    Last 12 quarters

    Frequently Asked Questions About VKTX

    What is Viking Therapeutics' annual revenue?

    Viking Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Viking Therapeutics profitable?

    No. Viking Therapeutics reported net income of -$359.64M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does VKTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$278.69M minus capital expenditures of $0 produced free cash flow of -$278.69M.

    How much debt does Viking Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $137.00K and cash and equivalents of $165.81M.